NASDAQ$MLYS

Mineralys Therapeutics Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.51

Previous: -$1.60+68.1%
Net Income

-$12.6M

Previous: -$7.57M-66.6%
Operating Income

-$14.9M

Previous: -$7.57M-97.4%
Cash & Equivalents

$138M

Previous: $16.1M+759.7%
Total Assets

$306M

No prior period
Stock-Based Comp

$749K

Previous: $19K+3842.1%

Revenue & EPS history

Mineralys Therapeutics · Revenue · Quarterly

$0

Q3 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 14 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-1.0%

Avg return

Earnings day

-5.9%

Avg return

5 days after

+5.5%

Avg return

30 days after

53%

8 / 15 earnings

Positive

+10.0%

Q4 2024

Best reaction

-9.2%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-2.9%-2.9%-21.3%
Q3 2025+5.9%-8.2%-19.0%
Q2 2025+0.4%+13.5%+174.6%
Q1 2025+2.6%+4.8%+6.1%
Q4 2024+10.0%+6.0%+47.5%
Q3 2024-4.7%-18.2%-7.8%
Q1 2024-7.7%-10.9%-10.3%
Q4 2023-4.1%-4.1%-15.7%
Q3 2022+0.7%-20.4%-14.8%
Q3 2023+0.7%-20.4%-14.8%
Q2 2023+0.5%-3.7%-8.9%
Q2 2022+0.5%-3.7%-8.9%
Q1 2023-4.3%-4.0%-1.2%
Q1 2022-4.3%-4.0%-1.2%
Q4 2022-9.2%-12.3%-22.0%
Q4 2021

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro